EGFR and non-small cell lung carcinoma: Notably, first-generation EGFR tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib, significantly reduced the tumor size and improved the overall survival of NSCLC patients with EGFR mutations [8,9,10,11].